evodiamine has been researched along with Esophageal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Hoffman, RM; Jia, L; Li, L; Li, M; Wang, F; Xu, T; Yuan, S; Zhang, L; Zhao, W | 1 |
| Feng, H; Guo, B; Kong, X; Wu, B | 1 |
2 other study(ies) available for evodiamine and Esophageal Neoplasms
| Article | Year |
|---|---|
Evodiamine inhibits ESCC by inducing M-phase cell-cycle arrest via CUL4A/p53/p21 axis and activating noxa-dependent intrinsic and DR4-dependent extrinsic apoptosis.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cullin Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Tumor Suppressor Protein p53 | 2023 |
[Evodiamine enhances the radiosensitivity of esophageal squamous cell cancer Eca-109 cells].
Topics: Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA-Activated Protein Kinase; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Humans; Ku Autoantigen; Nuclear Proteins; Plant Extracts; Quinazolines; Rad51 Recombinase; Radiation Tolerance; X-Rays | 2016 |